Table S1. The catalog numbers for all primary antibodies used in this research

Antibody Description	Manufacturer	Catalog numbers
anti-NFM	Abcam Biotechnology	ab9034
anti-MAP2	Abcam Biotechnology	ab11267
Anti-beta III Tubulin(Tuj1)	Abcam Biotechnology	ab78078
anti-NSE	Neuromics	CH23003
anti-GFAP	Neuromics	MO22136
BrdU	Santa Cruz	sc-32323
anti- Aurora B	Santa Cruz	sc-25426
anti-α-tubulin	Abcam Biotechnology	ab18251
anti-CD44	Abcam Biotechnology	ab19622
anti-CD29	Abcam Biotechnology	ab5185
anti-CD73	Santa Cruz	sc-25603
anti-histone acH3K9	Santa Cruz	sc-8655
anti-histone meH3K9	Abcam Biotechnology	ab8898
anti-Oct4(H-134)	Santa Cruz	sc-9081
anti-Sox2	CST	3579S
anti-Nanog	CST	3580



Figure S1 Cell cycle, cell apoptosis and immunodetection for BrdU incorporation of Reversine treated fibroblasts



Figure S2 Cell cycle changes of reversine-treated cells after reversine removed from 4th to 14th day



Figure S3 The conversion frequencies of fibroblasts to the target cell for immunofluorescence figures (MAP2, NSE, NFM, GFAP and TUJ-1)